iCAD (ICAD) Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iCAD in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ICAD shares.
View ICAD analyst ratings or view top-rated stocks.

4 brokerages have issued 1-year price objectives for iCAD's stock. Their ICAD share price forecasts range from $2.50 to $6.00. On average, they anticipate the company's share price to reach $3.90 in the next year. This suggests a possible upside of 212.0% from the stock's current price.
View analysts price targets for ICAD or view top-rated stocks among Wall Street analysts.

iCAD's stock was trading at $1.83 at the beginning of 2023. Since then, ICAD stock has decreased by 31.7% and is now trading at $1.25.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our ICAD earnings forecast.

iCAD, Inc. (NASDAQ:ICAD) issued its quarterly earnings results on Tuesday, March, 28th. The technology company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.01. The technology company earned $6.49 million during the quarter, compared to the consensus estimate of $6.53 million. iCAD had a negative trailing twelve-month return on equity of 37.50% and a negative net margin of 53.01%.

iCAD issued an update on its fourth quarter 2022 earnings guidance on Monday, March, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $6.50 million-$6.50 million, compared to the consensus revenue estimate of $6.61 million.

4 employees have rated iCAD Chief Executive Officer Michael Klein on Glassdoor.com. Michael Klein has an approval rating of 75% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other iCAD investors own include Inseego (INSG), Marvell Technology (MRVL), NVIDIA (NVDA), Aptiv (APTV), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Ambarella (AMBA), BioXcel Therapeutics (BTAI) and Telefonaktiebolaget LM Ericsson (publ) (ERIC).

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

iCAD's stock is owned by a variety of institutional and retail investors. Top institutional investors include Granahan Investment Management LLC (8.51%), Portolan Capital Management LLC (3.61%), Greenwood Capital Associates LLC (1.27%), General American Investors Co. Inc. (0.79%), Perritt Capital Management Inc. (0.79%) and Renaissance Technologies LLC (0.75%). Insiders that own company stock include Andy Sassine, Charles Ross Carter, Dana R Brown, Jonathan Go, Michael S Klein, R Scott Areglado, Stacey M Stevens, Susan Alyson Wood and Timothy Norris Irish.
View institutional ownership trends.

Shares of ICAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ICAD stock can currently be purchased for approximately $1.25.

iCAD (NASDAQ:ICAD) has a market capitalization of $31.81 million and generates $26.20 million in revenue each year. The technology company earns $-13,660,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.

The company employs 136 workers across the globe.

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The official website for the company is www.icadmed.com. The technology company can be reached via phone at (603) 882-5200, via email at jeremy@lifesciadvisors.com, or via fax at 603-880-3843.